Logo image of AGEN

AGENUS INC (AGEN) Stock Fundamental Analysis

NASDAQ:AGEN - Nasdaq - US00847G8042 - Common Stock - Currency: USD

3.32  -0.13 (-3.77%)

After market: 3.36 +0.04 (+1.2%)

Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to AGEN. AGEN was compared to 572 industry peers in the Biotechnology industry. AGEN may be in some trouble as it scores bad on both profitability and health. AGEN is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

AGEN had negative earnings in the past year.
In the past year AGEN has reported a negative cash flow from operations.
In the past 5 years AGEN always reported negative net income.
In the past 5 years AGEN reported 4 times negative operating cash flow.
AGEN Yearly Net Income VS EBIT VS OCF VS FCFAGEN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -50M -100M -150M -200M

1.2 Ratios

With a Return On Assets value of -95.55%, AGEN is not doing good in the industry: 74.25% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -95.55%
ROE N/A
ROIC N/A
ROA(3y)-45.6%
ROA(5y)-58.14%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
AGEN Yearly ROA, ROE, ROICAGEN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 100 -100 200 -200 300

1.3 Margins

AGEN has a better Gross Margin (99.61%) than 98.76% of its industry peers.
AGEN's Gross Margin has been stable in the last couple of years.
AGEN does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 99.61%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.23%
GM growth 5YN/A
AGEN Yearly Profit, Operating, Gross MarginsAGEN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -200 -400

More info and screens

0

2. Health

2.1 Basic Checks

AGEN does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for AGEN has been increased compared to 1 year ago.
Compared to 5 years ago, AGEN has more shares outstanding
Compared to 1 year ago, AGEN has a worse debt to assets ratio.
AGEN Yearly Shares OutstandingAGEN Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 5M 10M 15M
AGEN Yearly Total Debt VS Total AssetsAGEN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 100M 200M 300M 400M

2.2 Solvency

Based on the Altman-Z score of -14.29, we must say that AGEN is in the distress zone and has some risk of bankruptcy.
AGEN's Altman-Z score of -14.29 is on the low side compared to the rest of the industry. AGEN is outperformed by 81.53% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -14.29
ROIC/WACCN/A
WACC10.2%
AGEN Yearly LT Debt VS Equity VS FCFAGEN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 100M -100M -200M

2.3 Liquidity

AGEN has a Current Ratio of 0.19. This is a bad value and indicates that AGEN is not financially healthy enough and could expect problems in meeting its short term obligations.
The Current ratio of AGEN (0.19) is worse than 97.51% of its industry peers.
A Quick Ratio of 0.19 indicates that AGEN may have some problems paying its short term obligations.
With a Quick ratio value of 0.19, AGEN is not doing good in the industry: 97.34% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 0.19
Quick Ratio 0.19
AGEN Yearly Current Assets VS Current LiabilitesAGEN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 100M 200M 300M

More info and screens

6

3. Growth

3.1 Past

AGEN shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 31.46%, which is quite impressive.
AGEN shows a strong growth in Revenue. In the last year, the Revenue has grown by 59.00%.
Measured over the past years, AGEN shows a very strong growth in Revenue. The Revenue has been growing by 33.56% on average per year.
EPS 1Y (TTM)31.46%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%3.75%
Revenue 1Y (TTM)59%
Revenue growth 3Y21.03%
Revenue growth 5Y33.56%
Sales Q2Q%3.28%

3.2 Future

Based on estimates for the next years, AGEN will show a quite strong growth in Earnings Per Share. The EPS will grow by 10.14% on average per year.
Based on estimates for the next years, AGEN will show a quite strong growth in Revenue. The Revenue will grow by 11.23% on average per year.
EPS Next Y12.65%
EPS Next 2Y21.79%
EPS Next 3Y16.09%
EPS Next 5Y10.14%
Revenue Next Year-10.52%
Revenue Next 2Y6.19%
Revenue Next 3Y-0.72%
Revenue Next 5Y11.23%

3.3 Evolution

The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
AGEN Yearly Revenue VS EstimatesAGEN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 100M 200M 300M
AGEN Yearly EPS VS EstimatesAGEN Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 -10 -20

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

AGEN reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year AGEN is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
AGEN Price Earnings VS Forward Price EarningsAGEN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
AGEN Per share dataAGEN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 -5 -10

4.3 Compensation for Growth

A more expensive valuation may be justified as AGEN's earnings are expected to grow with 16.09% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y21.79%
EPS Next 3Y16.09%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for AGEN!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

AGENUS INC

NASDAQ:AGEN (2/21/2025, 8:00:20 PM)

After market: 3.36 +0.04 (+1.2%)

3.32

-0.13 (-3.77%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-12 2024-11-12/bmo
Earnings (Next)03-12 2025-03-12/amc
Inst Owners36.51%
Inst Owner Change-7.83%
Ins Owners1.37%
Ins Owner Change0.28%
Market Cap77.89M
Analysts74.55
Price Target8.16 (145.78%)
Short Float %12.65%
Short Ratio6.65
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly Dividend0
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-50.38%
Min EPS beat(2)-71.27%
Max EPS beat(2)-29.49%
EPS beat(4)1
Avg EPS beat(4)-59.05%
Min EPS beat(4)-142.76%
Max EPS beat(4)7.33%
EPS beat(8)3
Avg EPS beat(8)-28.4%
EPS beat(12)6
Avg EPS beat(12)-18.63%
EPS beat(16)9
Avg EPS beat(16)-12.49%
Revenue beat(2)0
Avg Revenue beat(2)-44.48%
Min Revenue beat(2)-62.51%
Max Revenue beat(2)-26.46%
Revenue beat(4)1
Avg Revenue beat(4)-11.73%
Min Revenue beat(4)-62.51%
Max Revenue beat(4)74.6%
Revenue beat(8)3
Avg Revenue beat(8)0.96%
Revenue beat(12)6
Avg Revenue beat(12)7.79%
Revenue beat(16)8
Avg Revenue beat(16)9.27%
PT rev (1m)0%
PT rev (3m)-17.95%
EPS NQ rev (1m)4.58%
EPS NQ rev (3m)-1748.73%
EPS NY rev (1m)1.52%
EPS NY rev (3m)-18.1%
Revenue NQ rev (1m)-27.32%
Revenue NQ rev (3m)-27.67%
Revenue NY rev (1m)-1.59%
Revenue NY rev (3m)-15.77%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.49
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-11.24
EYN/A
EPS(NY)-7.34
Fwd EYN/A
FCF(TTM)-7.28
FCFYN/A
OCF(TTM)-7.25
OCFYN/A
SpS6.84
BVpS-12.46
TBVpS-13.68
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -95.55%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 99.61%
FCFM N/A
ROA(3y)-45.6%
ROA(5y)-58.14%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.23%
GM growth 5YN/A
F-Score4
Asset Turnover0.67
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 4.75%
Cap/Sales 0.45%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.19
Quick Ratio 0.19
Altman-Z -14.29
F-Score4
WACC10.2%
ROIC/WACCN/A
Cap/Depr(3y)445.11%
Cap/Depr(5y)290.7%
Cap/Sales(3y)23.98%
Cap/Sales(5y)15.79%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)31.46%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%3.75%
EPS Next Y12.65%
EPS Next 2Y21.79%
EPS Next 3Y16.09%
EPS Next 5Y10.14%
Revenue 1Y (TTM)59%
Revenue growth 3Y21.03%
Revenue growth 5Y33.56%
Sales Q2Q%3.28%
Revenue Next Year-10.52%
Revenue Next 2Y6.19%
Revenue Next 3Y-0.72%
Revenue Next 5Y11.23%
EBIT growth 1Y52.76%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year12.05%
EBIT Next 3Y-4.29%
EBIT Next 5Y-7.26%
FCF growth 1Y14.02%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-12.65%
OCF growth 3YN/A
OCF growth 5YN/A